Clinicopathologic Features of Advanced Squamous NSCLC

Slides:

Advertisements

Similar presentations

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Advertisements

Advances in Molecular Biology of Lung Disease

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB (Alliance) Arnaud Augert, PhD,

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

SC17.02 Lung Cancer in China: Challenges and Perspectives

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD

Scientific Advances in Lung Cancer 2015

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification Anna Karlsson, MSc,

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Scientific Advances in Lung Cancer 2015

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung.

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification Anna Karlsson, MSc,

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer Alexa B. Schrock, PhD, Allison.

Robert Pirker, MD, Felix J. F. Herth, MD, PhD, FCCP, Keith M

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Frank Detterbeck, MD Journal of Thoracic Oncology

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing Marieke Hylebos, MSc, Guy Van Camp, PhD, Jan P van.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial

George Blumenschein, MD, John V. Heymach, MD, PhD

Liping Zhang, MD, Hui Yu, MD, PhD, Andrzej Badzio, MD, PhD, Theresa A

Matthias Scheffler, MD, Michaela A

CtDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study Martin Reck, MD, PhD, Koichi Hagiwara,

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Early Stage Lung Cancer: Progress in the Last 40 Years

Natural History and Factors Associated with Overall Survival in Stage IV ALK- Rearranged Non–Small Cell Lung Cancer Jose M. Pacheco, MD, Dexiang Gao,

Mitotic Inhibitors Journal of Thoracic Oncology

A Translational View of the Molecular Pathogenesis of Lung Cancer

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD,

Benjamin Solomon, MBBS, PhD, Richard B. Pearson, PhD

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Unusual Chemosensitivity of Advanced Bronchioalveolar Carcinoma after Gefitinib Response and Progression: A Case Report Rafal Dziadziuszko, MD, PhD,

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

Non-invasive Breath Analysis of Pulmonary Nodules

Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer Helen Chow, MD, Martin J.

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer Mark A. Socinski, MD, Coleman Obasaju, MD, PhD, David Gandara, MD, Fred R.

Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma Filippo Lococo, MD,

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 Jordi Remon, MD, Myung-Ju Ahn, MD, Nicolas Girard, MD, PhD, Melissa Johnson,

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Mark A. Socinski, MD Journal of Thoracic Oncology

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Clinicopathologic Features of Advanced Squamous NSCLC Mark A. Socinski, MD, Coleman Obasaju, MD, PhD, David Gandara, MD, Fred R. Hirsch, MD, Philip Bonomi, MD, Paul Bunn, MD, Edward S. Kim, MD, Corey J. Langer, MD, Ronald B. Natale, MD, Silvia Novello, MD, PhD, Luis Paz-Ares, MD, Maurice Pérol, MD, Martin Reck, MD, Suresh S. Ramalingam, MD, Craig H. Reynolds, MD, David R. Spigel, MD, Thomas E. Stinchcombe, MD, Heather Wakelee, MD, Carlos Mayo, MD, Nick Thatcher, MD, PhD Journal of Thoracic Oncology Volume 11, Issue 9, Pages 1411-1422 (September 2016) DOI: 10.1016/j.jtho.2016.05.024 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Relative risk for lung cancer based on smoking status in men. CI, confidence interval. Adapted with permission from Pesch et al.35 Copyright © 2012 John Wiley & Sons, Inc. All Rights Reserved. Journal of Thoracic Oncology 2016 11, 1411-1422DOI: (10.1016/j.jtho.2016.05.024) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Distribution of lung cancer by histologic type in (A) women and (B) men, 1998–2002. US, United States; UK, United Kingdom; sqCLC, squamous cell lung cancer. Adapted with permission from Youlden et al.38 Journal of Thoracic Oncology 2016 11, 1411-1422DOI: (10.1016/j.jtho.2016.05.024) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Estimated frequency of genetic alterations in squamous cell lung cancer based on analysis of 178 samples from The Cancer Genome Atlas study. Alterations were defined as somatic mutations, homozygous deletions, high-level focal amplifications, or significant upregulation or downregulation of gene expression. FGFR1, FGFR1 fibroblast growth factor receptor 1 gene; FGFR2, FGFR2 fibroblast growth factor receptor 2 gene; FGFR3, FGFR3 fibroblast growth factor receptor 3 gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; PTEN, phosphatase and tensin homolog; GRAF, GRAF Rho GTPase activating protein 26 gene; AKT3, AKT/serine threonine kinase 3 gene. Adapted with permission from the Cancer Genome Atlas Research Network.69 Copyright © 2012 International Association for the Study of Lung Cancer. Journal of Thoracic Oncology 2016 11, 1411-1422DOI: (10.1016/j.jtho.2016.05.024) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions